{"id":4162,"date":"2016-09-01T08:08:11","date_gmt":"2016-09-01T12:08:11","guid":{"rendered":"https:\/\/medicarereport.org\/?p=4162"},"modified":"2016-09-01T08:08:11","modified_gmt":"2016-09-01T12:08:11","slug":"mylans-generic-epipen-a-price-break-or-marketing-maneuver","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=4162","title":{"rendered":"Mylan\u2019s Generic EpiPen \u2014 A Price Break Or Marketing Maneuver?"},"content":{"rendered":"<p>(By Julie Appleby for Kaiser Health News)<\/p>\n<p>Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said Monday it will offer a <a href=\"http:\/\/www.npr.org\/sections\/health-shots\/2016\/08\/29\/491797051\/maker-of-epipen-to-sell-generic-version-for-half-the-price\" target=\"_blank\">generic version<\/a> of the life-saving allergy treatment. The generic, which the company says will be identical to the brand product, will sell for $300 for a two-pack, which is half the cost of Mylan\u2019s brand name EpiPens. The news did little to dim the ongoing outcry over the price, for which there are no other competitors on the market. Some called it a marketing ploy, while Robert Weissman, president of the consumer group Public Citizen, said the generic price was <a href=\"http:\/\/www.huffingtonpost.com\/robert-weissman\/epipen-makers-latest-offe_b_11760170.html\" target=\"_blank\">still too high<\/a>, writing in the Huffington Post of \u201cthe weirdness of a drug company offering a generic version\u201d of its own brand-name product. <a href=\"http:\/\/khn.org\/news\/mylans-generic-epipen-a-price-break-or-marketing-maneuver\/?utm_campaign=KHN%3A+First+Edition&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=33705355&amp;_hsenc=p2ANqtz-9v2DUz0dcSdcPPWlYpd7I8dEEL8yGD4eJhq05Drc520DeG4n9TZ6lXnqYVbXJV5XtdJM1JAv5qEeI5TEXIu2NdbZhn_A&amp;_hsmi=33705355\" target=\"_blank\">Continue reading article here&#8230;..<\/a><\/p>\n<p style=\"margin: 0px 0px 15px; padding: 0px; outline: 0px; border: 0px currentColor; color: #444444; text-transform: none; line-height: 1.6; text-indent: 0px; letter-spacing: normal; font-family: 'Open Sans', serif; font-size: 15px; font-style: normal; font-weight: normal; word-spacing: 0px; vertical-align: baseline; white-space: normal; orphans: 2; widows: 2; font-stretch: inherit; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; font-variant-numeric: inherit; -webkit-text-stroke-width: 0px;\">Kaiser Health News\u00a0is\u00a0a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.<\/p>\n<p style=\"font: 15px\/1.6 'Open Sans', serif; margin: 0px 0px 15px; padding: 0px; outline: 0px; border: 0px currentColor; color: #444444; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; vertical-align: baseline; white-space: normal; orphans: 2; widows: 1; font-size-adjust: none; font-stretch: inherit; background-color: #ffffff; -webkit-text-stroke-width: 0px;\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-899 \" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-300x156.png\" alt=\"khn-logo1\" width=\"92\" height=\"48\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-300x156.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-1024x533.png 1024w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-390x205.png 390w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1.png 1600w\" sizes=\"auto, (max-width: 92px) 100vw, 92px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Julie Appleby for Kaiser Health News) Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-4162","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4162"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4162\/revisions"}],"predecessor-version":[{"id":4163,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4162\/revisions\/4163"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}